Lect. PhD DENİZ CANSEN KAHRAMAN

ATLAS Publication Analytics

Articles 25

1. Enzyme-Targeted Antiproliferative Effects of Novel Indole–Acrylamide Xenobiotics Acting on Cyclooxygenase Pathways

Hawash M., Mahmutoğlu B., Abualhasan M., Kahraman D. C., Baytas S. N.

JOURNAL OF XENOBIOTICS , vol.16, no.2, pp.1-19, 2026 (ESCI, Scopus)

2. Target-specific de novo design of drug candidate molecules with graph-transformer-based generative adversarial networks

Ünlü A., Çevrim E., Yiğit M. G., Sarıgün A., Çelikbilek H., Bayram O., et al.

Nature Machine Intelligence , vol.7, no.9, pp.1524-1540, 2025 (SCI-Expanded, Scopus) Sustainable Development

3. Design, synthesis, and evaluation of novel Indole-Based small molecules as sirtuin inhibitors with anticancer activities.

Binarci B., Kilic E. K., Dogan T., Cetin Atalay R., Kahraman D. C., Nacak Baytas S.

Drug development research , vol.85, no.7, 2024 (SCI-Expanded, Scopus)

4. Design, synthesis, molecular docking studies and biological evaluation of thiazole carboxamide derivatives as COX inhibitors

Hawash M., Jaradat N., Abualhasan M., ŞÜKÜROĞLU M. K., Qaoud M. T., KAHRAMAN D. C., et al.

BMC Chemistry , vol.17, no.1, 2023 (SCI-Expanded, Scopus)

5. Novel indole-pyrazole hybrids as potential tubulin-targeting agents; Synthesis, antiproliferative evaluation, and molecular modeling studies

Hawash M., Ergun S. G., KAHRAMAN D. C., OLĞAÇ A., Hamel E., Cetin-Atalay R., et al.

Journal of Molecular Structure , vol.1285, 2023 (SCI-Expanded, Scopus)

6. A new triazolothiadiazine derivative inhibits stemness and induces cell death in HCC by oxidative stress dependent JNK pathway activation

KAHRAMAN D. C., Guven E. B., Aytac P. S., Aykut G., Tozkoparan B., Atalay R. C.

SCIENTIFIC REPORTS , vol.12, no.1, 2022 (SCI-Expanded, Scopus) Sustainable Development

7. Low Density Granulocytes and Dysregulated Neutrophils Driving Autoinflammatory Manifestations in NEMO Deficiency

Yilmaz N. S., Eltan S. B., KAYAOĞLU B., Geckin B., Heredia R. J., Sefer A. P., et al.

JOURNAL OF CLINICAL IMMUNOLOGY , vol.42, no.3, pp.582-596, 2022 (SCI-Expanded, Scopus)

8. Design and synthesis of novel substituted indole-acrylamide derivatives and evaluation of their anti-cancer activity as potential tubulin-targeting agents

Hawash M., KAHRAMAN D. C., OLĞAÇ A., Ergun S. G., Hamel E., Cetin-Atalay R., et al.

JOURNAL OF MOLECULAR STRUCTURE , vol.1254, 2022 (SCI-Expanded, Scopus) Sustainable Development

9. Context dependent isoform specific PI3K inhibition confers drug resistance in hepatocellular carcinoma cells.

Narci K., Kahraman D. C., Koyas A., Ersahin T., Tuncbag N., Atalay R. C.

BMC cancer , vol.22, no.1, pp.320, 2022 (SCI-Expanded, Scopus)

10. Data Centric Molecular Analysis and Evaluation of Hepatocellular Carcinoma Therapeutics Using Machine Intelligence-Based Tools

Cetin-Atalay R., Kahraman D. C., Nalbat E., Rifaioğlu A. S., Atakan A., Dönmez A., et al.

JOURNAL OF GASTROINTESTINAL CANCER , vol.52, no.4, pp.1266-1276, 2021 (ESCI, Scopus)

11. Synthesis of novel indole-isoxazole hybrids and evaluation of their cytotoxic activities on hepatocellular carcinoma cell lines

Hawash M., KAHRAMAN D. C., Ergun S. G., Cetin-Atalay R., BAYTAŞ S.

BMC CHEMISTRY , vol.15, no.1, 2021 (SCI-Expanded, Scopus)

12. Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells

Ibis K., NALBAT E., ÇALIŞKAN B., KAHRAMAN D. C., Cetin-Atalay R., BANOĞLU E.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , vol.221, 2021 (SCI-Expanded, Scopus) Sustainable Development

13. Induction of Apoptosis in Hepatocellular Carcinoma Cell Lines by Novel Indolylacrylamide Derivatives: Synthesis and Biological Evaluation

Hawash M., Kahraman D. C., Cetin-Atalay R., BAYTAŞ S.

CHEMISTRY & BIODIVERSITY , vol.18, no.5, 2021 (SCI-Expanded, Scopus) Sustainable Development

14. MDeePred: Novel multi-channel protein featurization for deep learning-based binding affinity prediction in drug discovery

Rifaioglu A., Atalay R. C., KAHRAMAN D. C., DOĞAN T., Martin M., ATALAY M. V.

Bioinformatics , vol.37, no.5, pp.693-704, 2021 (SCI-Expanded, Scopus) Sustainable Development

15. Transcriptome profiles associated with selenium-deficiency-dependent oxidative stress identify potential diagnostic and therapeutic targets in liver cancer cells

Gozen D., KAHRAMAN D. C., Narci K., Shehwana H., KONU KARAKAYALI Ö., Cetin-Atalay R.

TURKISH JOURNAL OF BIOLOGY , vol.45, no.2, pp.149-164, 2021 (SCI-Expanded, Scopus, TRDizin) Sustainable Development

16. CXXC5 as an unmethylated CpG dinucleotide binding protein contributes to estrogen-mediated cellular proliferation.

Ayaz G., Razizadeh N., Yaşar P., Kars G., Kahraman D. C., Saatci Ö., et al.

Scientific reports , vol.10, pp.5971, 2020 (SCI-Expanded, Scopus) Sustainable Development

17. Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment

KAHRAMAN D. C., Kahraman T., Cetin-Atalay R.

MOLECULAR CANCER THERAPEUTICS , vol.18, no.11, pp.2146-2157, 2019 (SCI-Expanded, Scopus)

18. Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine-(thio)urea hybrids as potential kinase inhibitors.

Ture A., Kahraman D. C., Cetin-Atalay R., Helvacioglu S., Charehsaz M., KÜÇÜKGÜZEL İ.

Computational biology and chemistry , vol.78, pp.227-241, 2019 (SCI-Expanded, Scopus) Sustainable Development

19. Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents.

Inceler N., ÖZKAN Y., Turan N. N., Kahraman D. C., Cetin-Atalay R., BAYTAŞ S.

MedChemComm , vol.9, no.5, pp.795-811, 2018 (SCI-Expanded, Scopus) Sustainable Development

20. Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics.

Hawash M. M. A., Kahraman D. C., Eren F., Atalay R. C., BAYTAŞ S.

European journal of medicinal chemistry , vol.129, pp.12-26, 2017 (SCI-Expanded, Scopus)

21. Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells.

Kahraman D. C., Hanquet G., Jeanmart L., Lanners S., Sramel P., Bohac A., et al.

MedChemComm , vol.8, no.1, pp.81-87, 2016 (SCI-Expanded, Scopus) Sustainable Development

22. Phase and TV Based Convex Sets for Blind Deconvolution of Microscopic Images

Tofighi M., Yorulmaz O., Koese K., Yildirim D. C., Cetin-Atalay R., ÇETİN A. E.

IEEE JOURNAL OF SELECTED TOPICS IN SIGNAL PROCESSING , vol.10, no.1, pp.81-91, 2016 (SCI-Expanded, Scopus)

23. Ynamide Click chemistry in development of triazole VEGFR2 TK modulators.

Vojtickova M., Dobias J., Hanquet G., Addova G., Cetin-Atalay R., Yildirim D. C., et al.

European journal of medicinal chemistry , vol.103, pp.105-22, 2015 (SCI-Expanded, Scopus)

24. Application of the Ugi reaction with multiple amino acid-derived components: synthesis and conformational evaluation of piperazine-based minimalist peptidomimetics.

Stucchi M., Cairati S., Cetin-Atalay R., Christodoulou M. S., Grazioso G., Pescitelli G., et al.

Organic & biomolecular chemistry , vol.13, no.17, pp.4993-5005, 2015 (SCI-Expanded, Scopus)

25. Near-IR absorbing BODIPY derivatives as glutathione-activated photosensitizers for selective photodynamic action.

Turan I., Cakmak F., Yildirim D. C., Cetin-Atalay R., Akkaya E.

Chemistry (Weinheim an der Bergstrasse, Germany) , vol.20, pp.16088-92, 2014 (SCI-Expanded, Scopus)

Papers Presented at Peer-Reviewed Scientific Conferences 35

1. SAT-163 Inflammation-associated gene expression profiles distinguishing significant fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD): evidence from a Turkish patient cohort

Kahraman D. C., Nalbat E., Turan Gökçe D., Kiremitci S., İdilman R.

EASL Congress 2026, Barcelona, Spain, 27 - 30 May 2026, pp.652, (Summary Text)

2. Inflammation-associated gene expression profiles distinguishing significant fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD): evidence from a Turkish patient cohort

KAHRAMAN D. C., NALBAT E., TURAN GÖKÇE D., KİREMİTCİ S., İDİLMAN R.

Congress of the European-Association-for-the-Study-of-the-Liver Congress (EASL), Barcelona, Spain, 27 - 30 May 2026, vol.84, (Summary Text)

3. Unveiling Molecular Biomarkers of MASLD Fibrosis: A Transcriptomic and Pathway Enrichment Analysis

NALBAT E., KAHRAMAN D. C.

AASLD-TASL Hepatology Connect Meeting 2025, İstanbul, Turkey, 14 - 15 February 2025, (Summary Text)

4. Deciphering Transcriptional Landscapes of Mild and Advanced MASLD Fibrosis: Insights into Differential Gene Expression, Pathway Enrichment, and Drug Repurposing Opportunities

NALBAT E., KAHRAMAN D. C.

17th International Symposium on Health Informatics and Bioinformatics, İstanbul, Turkey, 18 - 20 December 2024, (Summary Text)

5. Targeting sirtuins with novel indole derivatives: implications for anticancer activity in hepatocellular carcinoma

BINARCI B., DOĞAN T., ATALAY R., KAHRAMAN D. C., BAYTAŞ S.

EASL Liver Cancer Summit 2024, Rotterdam, Netherlands, 22 - 24 February 2024, (Summary Text)

6. Exploring early markers of fibrosis progression in metabolic dysfunction–associated steatotic liver disease in Turkiye

KAHRAMAN D. C., NALBAT E., ATALAY R., İDİLMAN R.

AASLD-TASL Connect Meeting 2024, İzmir, Turkey, 16 - 17 February 2024, (Summary Text)

7. Repurposing Drugs to Target Molecular Networks in Hepatocellular Carcinoma Cells & Stem Cells for Innovative Treatment Strategies

NALBAT E., TUNÇBAĞ N., KAHRAMAN D. C., ATALAY R.

4th Open Research Day, Turkey, 01 December 2023, (Summary Text)

8. DeepResponse: Large Scale Prediction of Cancer Cell Line Drug Response with Deep Learning Based Pharmacogenomic Modelling

KAHRAMAN D. C., DOĞAN T.

16th International Symposium on Health Informatics and Bioinformatics (HIBIT 2023), Ankara, Turkey, 4 - 06 October 2023, (Summary Text)

9. Anti-Cancer and Anti-Stemness Action of Nonsteroidal Anti-Inflammatory Agents: A Special Focus on Hepatocellular Carcinoma

KAHRAMAN D. C.

3rd International Multidisciplinary Cancer Research Congress, İstanbul, Turkey, 7 - 10 September 2023, (Summary Text)

10. Network-based drug repurposing approach identifies novel drugs and drug combinations against HCC

NALBAT E., TUNÇBAĞ N., KAHRAMAN D. C., ATALAY R.

AASLD-TASL Digital Hepatology Meeting, Ankara, Turkey, 28 - 29 April 2023, (Summary Text)

11. Experimental validation of drug responses predicted by deep learning-based bioactivity models in hepatocellular carcinoma cell lines

KAHRAMAN D. C., DOĞAN T.

15th International Symposium on Health Informatics and Bioinformatics (HIBIT 2022), Mersin, Turkey, 20 - 22 October 2022, (Summary Text)

12. A Multi-Omics and Machine Learning-Based Predictor of Drug Sensitivity in Cancer

KAHRAMAN D. C., DOĞAN T.

15th International Symposium on Health Informatics and Bioinformatics (HIBIT 2022), Mersin, Turkey, 20 - 22 October 2022, (Summary Text)

13. Automated prediction of drug response in HCC cell lines with deep learning-based bioactivity modeling and experimental validation

KAHRAMAN D. C., AKAR E., DOĞAN T.

EACR 2022, Sevilla, Spain, 20 - 23 June 2022, (Summary Text)

14. Synergistic effect of sorafenib in combination with naproxen on hepatocellular carcinoma cell lines

AKAR E., KAHRAMAN D. C.

EACR 2022, Sevilla, Spain, 20 - 23 June 2022, (Summary Text)

15. A NEW THIADIAZINE DERIVATIVE INDUCES OXIDATIVE STRESS DEPENDENT CELL DEATH IN HEPATOCELLULAR CARCINOMA STEM CELLS

KAHRAMAN D. C., GÜVEN E. B., Aytac P., TOZKOPARAN KÖPRÜCÜ B., ATALAY R.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70, (Summary Text)

16. A new thiadiazine derivative induces oxidative stress dependent JNK pathway activation and cell death in hepatocellular carcinoma

KAHRAMAN D. C., GÜVEN E. B., TOZKOPARAN KÖPRÜCÜ B., ATALAY R.

Annual Meeting of the American-Association-for-Cancer-Research (AACR), Georgia, United States Of America, 29 March - 03 April 2019, vol.79, (Summary Text)

17. Abstract 996: In silico modeling and in vitro validation of undefined off-target of drugs in hepatocellular carcinoma

NALBAT E., TUNÇBAĞ N., KAHRAMAN D. C., ATALAY R.

AACR Annual Meeting 2019, Atlanta, United States Of America, 29 March - 03 April 2019, (Summary Text)

18. In silico modeling and in vitro validation of undefined off-target of drugs in hepatocellular carcinoma

Sinoplu E., Tuncbag N., Kahraman D. C., Atalay R. C.

Annual Meeting of the American-Association-for-Cancer-Research (AACR), Georgia, United States Of America, 29 March - 03 April 2019, vol.79, (Summary Text)

19. Effects of small molecule inhibitors on liver cancer stem cells in comparison with Sorafenib

KAHRAMAN D. C., ATALAY R.

AASLD-TASL Connect Meeting 2019, İstanbul, Turkey, 15 - 16 March 2019, (Summary Text)

20. Identification of interleukin 8 as a cancer stem cell enrichment stimulating factor in HCC

KAHRAMAN D. C., ATALAY R.

11th International Symposium on Health Informatics and Bioinformatics (HIBIT 2018), Antalya, Turkey, 25 - 27 October 2018, (Summary Text)

21. Differential alteration of IL-8 in liver cancer stem cell enrichment in response to PI3K/Akt/mTOR inhibitors and sorafenib

Kahraman D. C., Kahraman T., ATALAY R.

American Association for Cancer Research Annual Meeting 2018, Chicago, United States Of America, 12 - 18 April 2018, vol.78, pp.3937, (Summary Text) Sustainable Development

22. Differential alteration of IL-8 in response to Sorafenib and PI3K/Akt/mTOR inhibitors in liver cancer cells and in liver cancer stem cells

KAHRAMAN D. C., ATALAY R.

AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Philadelphia, United States Of America, 26 - 30 October 2017, (Summary Text)